The Reimbursement Dependency Trap: 54 Companies That Built Before the Codes Existed

The pattern

Reimbursement dependency is the most common failure node after competitive displacement in the Stressline corpus — 54 deaths. These companies built products that required CPT codes, payer coverage, or CMS reimbursement pathways that either didn't exist at launch or paid too little to sustain the business model.

Where it hits hardest

Digital therapeutics leads with the highest concentration of reimbursement-dependent failures. Companies like Pear Therapeutics ($409M raised) built FDA-cleared digital therapeutic products, then discovered that payer adoption of the relevant reimbursement codes was too slow to generate sustainable revenue.

The pattern also appears heavily in:

• **Telehealth infrastructure** — companies that built assuming pandemic-era reimbursement parity would become permanent
• **Behavioral health** — where reimbursement rates are structurally lower than physical health and coverage gaps are wider
• **Care coordination** — where coordination payments exist but are often carved out or time-limited

The structural problem

Reimbursement dependency is a timing trap. The company builds a clinically valid product. The clinical evidence is real. The patient outcomes improve. But the reimbursement pathway lags by 2-5 years, and the company runs out of capital before the codes catch up.

What separates survivors

The corpus shows that companies in the same sub-verticals who survived typically did one of three things:

• Sold to self-insured employers who don't need CPT codes
• Built a cash-pay model first and added reimbursement later
• Targeted existing codes (99490, 99457) rather than waiting for new ones

By the numbers

• **54 deaths** from reimbursement dependency
• **$4.1B** in total funding burned
• Median time from founding to closure: 4.2 years